1. Market Research
  2. > Samyang Holdings Corporation - Product Pipeline Review - 2013

Samyang Holdings Corporation - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 47 pages

Samyang Holdings Corporation - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Samyang Holdings Corporation - Product Pipeline Review - 2013” provides data on the Samyang Holdings Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Samyang Holdings Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Samyang Holdings Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Samyang Holdings Corporation - Brief Samyang Holdings Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Samyang Holdings Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Samyang Holdings Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Samyang Holdings Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Samyang Holdings Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Samyang Holdings Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Samyang Holdings Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Samyang Holdings Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Samyang Holdings Corporation and identify potential opportunities in those areas.

Table Of Contents

Samyang Holdings Corporation - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 5
List of Figures 5
Samyang Holdings Corporation Snapshot 6
Samyang Holdings Corporation Overview 6
Key Information 6
Key Facts 6
Samyang Holdings Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Samyang Holdings Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Samyang Holdings Corporation - Pipeline Products Glance 12
Samyang Holdings Corporation Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Samyang Holdings Corporation - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Samyang Holdings Corporation - Drug Profiles 15
aprepitant 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
candesartan cilexetil 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
capsaicin Patch 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
celecoxib 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
docetaxel 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
docetaxel-PM 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
fenofibrate 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
goserelin Sustained Release 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Human Growth Hormone Sustained Release 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
methylphenidate Fast Dissolving Tablet 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
paclitaxel 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
paclitaxel-loaded polymeric micelle 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
risperidone Fast Dissolving Tablet 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
rivastigmine 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
siRNA 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
sirolimus 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
tacrolimus 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
tacrolimus Fast Dissolving Tablet 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
voriconazole 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Samyang Holdings Corporation - Pipeline Analysis 35
Samyang Holdings Corporation - Pipeline Products by Therapeutic Class 35
Samyang Holdings Corporation - Pipeline Products by Route of Administration 37
Samyang Holdings Corporation - Pipeline Products By Mechanism of Action 38
Samyang Holdings Corporation - Recent Pipeline Updates 40
Samyang Holdings Corporation - Dormant Projects 41
Samyang Holdings Corporation - Company Statement 42
Samyang Holdings Corporation - Locations And Subsidiaries 43
Head Office 43
Other Locations and Subsidiaries 43
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables


Samyang Holdings Corporation, Key Information 6
Samyang Holdings Corporation, Key Facts 6
Samyang Holdings Corporation - Pipeline by Indication, 2013 9
Samyang Holdings Corporation - Pipeline by Stage of Development, 2013 10
Samyang Holdings Corporation - Monotherapy Products in Pipeline, 2013 11
Samyang Holdings Corporation - Phase II, 2013 12
Samyang Holdings Corporation - Phase I, 2013 13
Samyang Holdings Corporation - Pre-Clinical, 2013 14
Samyang Holdings Corporation - Pipeline By Therapeutic Class, 2013 36
Samyang Holdings Corporation - Pipeline By Route of Administration, 2013 37
Samyang Holdings Corporation - Pipeline Products By Mechanism of Action, 2013 39
Samyang Holdings Corporation - Recent Pipeline Updates, 2013 40
Samyang Holdings Corporation - Dormant Developmental Projects,2013 41
Samyang Holdings Corporation, Other Locations 43
Samyang Holdings Corporation, Subsidiaries 43

List of Figures


Samyang Holdings Corporation - Pipeline by Indication, 2013 8
Samyang Holdings Corporation - Pipeline by Stage of Development, 2013 10
Samyang Holdings Corporation - Monotherapy Products in Pipeline, 2013 11
Samyang Holdings Corporation - Pipeline By Therapeutic Class, 2013 35
Samyang Holdings Corporation - Pipeline By Route of Administration, 2013 37
Samyang Holdings Corporation - Pipeline Products By Mechanism of Action, 2013 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.